Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 3 studies | 25% ± 2% | |
glutamatergic neuron | 3 studies | 30% ± 3% |
Insufficient scRNA-seq data for expression of MBLAC2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 797.06 | 2632 / 2642 | 100% | 6.11 | 704 / 705 |
esophagus | 99% | 399.73 | 1432 / 1445 | 100% | 5.13 | 183 / 183 |
intestine | 100% | 424.40 | 962 / 966 | 99% | 4.34 | 523 / 527 |
breast | 100% | 459.75 | 457 / 459 | 99% | 6.15 | 1109 / 1118 |
ovary | 99% | 654.91 | 179 / 180 | 99% | 5.27 | 427 / 430 |
thymus | 99% | 370.64 | 648 / 653 | 99% | 5.30 | 598 / 605 |
prostate | 100% | 400.14 | 244 / 245 | 98% | 6.10 | 494 / 502 |
adrenal gland | 98% | 380.23 | 254 / 258 | 98% | 6.35 | 225 / 230 |
kidney | 99% | 259.02 | 88 / 89 | 97% | 5.10 | 874 / 901 |
uterus | 100% | 608.70 | 170 / 170 | 96% | 3.91 | 439 / 459 |
skin | 100% | 573.75 | 1803 / 1809 | 96% | 7.55 | 452 / 472 |
bladder | 100% | 468.95 | 21 / 21 | 95% | 3.42 | 480 / 504 |
stomach | 96% | 253.78 | 344 / 359 | 99% | 4.55 | 282 / 286 |
pancreas | 100% | 318.20 | 327 / 328 | 94% | 2.91 | 167 / 178 |
liver | 100% | 351.28 | 226 / 226 | 92% | 2.87 | 374 / 406 |
lung | 85% | 227.76 | 491 / 578 | 99% | 3.86 | 1139 / 1155 |
spleen | 100% | 331.60 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 393.97 | 1199 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 354.78 | 1322 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 4.16 | 41 / 45 |
lymph node | 0% | 0 | 0 / 0 | 90% | 3.64 | 26 / 29 |
muscle | 89% | 179.30 | 718 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 88% | 4.63 | 70 / 80 |
heart | 85% | 188.54 | 733 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 26% | 185.92 | 245 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006631 | Biological process | fatty acid metabolic process |
GO_0008150 | Biological process | biological_process |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005886 | Cellular component | plasma membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0052816 | Molecular function | long-chain fatty acyl-CoA hydrolase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0008800 | Molecular function | beta-lactamase activity |
Gene name | MBLAC2 |
Protein name | Acyl-coenzyme A thioesterase MBLAC2 (Acyl-CoA thioesterase MBLAC2) (EC 3.1.2.2) (Beta-lactamase MBLAC2) (EC 3.5.2.6) (Metallo-beta-lactamase domain-containing protein 2) (Palmitoyl-coenzyme A thioesterase MBLAC2) |
Synonyms | |
Description | FUNCTION: Acyl-CoA thioesterases are a group of enzymes that catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A (CoASH), providing the potential to regulate intracellular levels of acyl-CoAs, free fatty acids and CoASH . Has an acyl-CoA thioesterase activity towards the long chain fatty acyl-CoA thioester palmitoyl-CoA (hexadecanoyl-CoA; C16:0-CoA) . Displays a substrate preference for fatty acyl-CoAs with chain-lengths C12-C18 . Possesses beta-lactamase activity, catalyzing the hydrolysis of penicillin G and nitrocefin . Exhibits no activity towards other beta-lactam antibiotic classes including cephalosporins (cefotaxime) and carbapenems (imipenem) . . |
Accessions | ENST00000316610.7 [Q68D91-1] Q68D91 ENST00000514906.1 [Q68D91-2] |